Immune Thrombocytopenia Induced by Sintilimab in Lung Cancer: 
A Case Report and Literature Review

Abstract

Immune checkpoint inhibitors (ICIs) show unique advantages in the treatment of lung cancer, making the treatment of lung cancer enter the era of immunotherapy, but ICIs will also have adverse reactions, and the incidence of immune-induced hematological toxicity is not very high. Immunotherapy-induced thrombocytopenia is a rare adverse event.We report one case of thrombocytopenia induced by ICIs and review the literature on thrombocytopenia associated with ICIs and discuss the clinical features, possible mechanisms, and optimal treatment.

Keywords

• immune checkpoint inhibitors
• sintilimab injection
• immune thrombocytopenia
• lung neoplasms
• immune-related adverse events